Combination therapy of specific aeroallergens immunotherapy and omalizumab, in children with severe asthma
Main Article Content
Keywords
children, omalizumab, severe asthma, specific aeroallergen immunotherapy
Abstract
Background: In most cases, severe asthma in children has an allergic etiology, but allergen-specific immunotherapy (AIT) is contraindicated.
Objective: This study aimed at analyzing the safety and efficacy of AIT in patients with severe asthma treated with omalizumab (OM).
Methods: A descriptive real-life study was carried out by reviewing medical records. Effectiveness was measured by the degree of control (CAN questionnaire), number of hospitalizations per year, number of exacerbations per year, and maintenance treatment and lung function (FEV1). Some adverse reactions occurred (AAI-EAACI-WAO guidelines).
Results: The retrospective study included 29 patients up to 18 years of age with severe asthma with OM plus AIT treatment. AIT treatment was started in a cluster schedule when patients treated with OM achieved disease control. Before starting AIT, patients were treated with OM for 1 year for achieving asthmatic control. AIT to mites (51%), Alternaria (37.9%), or pollens (10.3%) was administered. After one year with OM plus AIT,statistically significant differences in CAN scores and FEV1 measures were observed (P < 0.001). No patients under treatment with OM plus AIT required hospital admission. During the clustering schedule, only 3/64 doses showed systemic adverse reactions. During the AIT maintenance treatment, 348 doses were administered, with no significant adverse reactions.
Conclusion: In this population-based study in children with severe asthma, the combined treatment with OM plus AIT was safe and effective. This strategy allows these pediatric patients to be safely treated with AIT.
References
2. Fitzpatrick A, Moore W. Severe asthma phenotypes-How should they guide evaluation and treatment? J Allergy Clin Immunol Pract. 2017;5(4):901–8.10.1016/j.jaip.2017.05.015
3. Fleming L, Murray C, Bansal AT, Hashimoto S, Bisgaard H, Bush A, et al. The burden of severe asthma in childhood and adolescence: Results from the paediatric U-BIOPRED cohorts. Eur Respir J. 2015; 46:1322–33. 10.1183/13993003.00780-2015
4. Alvaro-Lozano M, Akdis CA, Alviani C, Angier E, Arasi S, et al. EAACI allergen immunotherapy user’s guide Pediatr Allergy Immunol. 2020;31(25):1–101. 10.1111/pai.13189
5. Pajno GB, Castagnoli R, Muraro A, Alvaro-Lozano M, Akdis CA, Akdis M, et al. Allergen immunotherapy for IgE-mediated food allergy: There is a measure in everything to a proper proportion of therapy. Pediatr Allergy Immunol. 2019;30(4):415–22. 10.1111/pai.13042.
6. Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth van Wijk R, et al. EAACI guidelines on allergen immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018;73(4):765–98. 10.1111/all.13317
7. Maglione M, Poeta M, Santamaria F. New drugs for pediatric asthma. Front Pediatr. 2019; 6:432. 10.3389/fped.2018.00432
8. Braido F, Corsico A, Rogkakou A, Ronzoni V, Baiardini I, Canonica GW. The relationship between allergen immunotherapy and omalizumab for treating asthma. Expert Rev Respir Med. 2015;, 9(2):129–34. 10.1586/17476348.2015.1000866
9. Licari A, Marseglia A, Caimmi S, Castagnoli R, Foiadelli T, Barberi S, Marseglia GL. Omalizumab in children. Paediatr Drugs. 2014;16(6):491–502. 10.1007/s40272-014-0107-z.
10. Carrier C, Demoly P, Caimmi D. [Omalizumab and allergen immunotherapy: A clinical report and review of the literature]. Rev Mal Respir. 2019;36(2):191–6. French. 10.1016/j.rmr.2018.03.006
11. Del Rodriguez RP, Vidal C, Just J, Tabar AI, Sanchez-Machin I, Eberle P, et al. The European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): A paediatric assessment. Pediatr Allergy Immunol. 2017;28(1):60–70. 10.1111/pai.12660
12. Calderon MA, Vidal C, Rodriguez Del Rio P, Just J, Pfaar O, Tabar AI, et al. European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): A real-life clinical assessment. Allergy. 2017;72(3):462–72. 10.1111/all.13066
13. Howarth P, Malling H-J, Molimard M, Devillier P. Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients. Allergy. 2012;67(3):321–7. 10.1159/000452333
14. Schiappoli M, Ridolo E, Senna G, Alesina R, Antonicelli L, Asero R, et al. A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy. Clin Exp Allergy. 2009;39(10):1569–74. 10.1111/j.1365-2222.2009.03286.x
15. Tsai T-C, Lu J-H, Chen S-J, Tang R-B. Clinical efficacy of house dust mite-specific immunotherapy in asthmatic children. Pediatr Neonatol. 2010;51:14–8. 10.1016/S1875-9572(10)60004-6
16. Lambert N, Guiddir T, Amat F, Just J. Pre-treatment by omalizumab allows allergen immunotherapy in children and young adults with severe allergic asthma. Pediatr Allergy Immunol. 2014;25(8):829–32. 10.1111/pai.12306
17. Carrier C, Demoly P, Caimmi D. [Omalizumab and allergen immunotherapy: A clinical report and review of the literature]. Revue des Maladies Respiratoires. 2019;36(2):191–6. 10.1016/j.rmr.2018.03.006
18. Dantzer JA, Wood RA. The use of omalizumab in allergen immunotherapy. Clin Exp Allergy. 2018;48(3):232–40. 10.1111/cea.13084
19. Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol. 2010;125(2):383–9. 10.1016/j.jaci.2009.11.022
20. Har D, Jung Lee M. Systemic reaction rates with omalizumab, subcutaneous immunotherapy, and combination therapy in children with allergic asthma. Allergy Asthma Proc. 2019;40:35–40. 10.2500/aap.2019.40.4173
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.